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The effectiveness of recombinant vaccines encoding full-length M2 protein of influenza virus or its ectodomain (M2e) have
previously been tested in a number of models with varying degrees of success. Recently, we reported a strong cytotoxic effect
exhibited by M2 on mammalian cells in vitro. Here we demonstrated a decrease in protection when M2 was added to a DNA
vaccination regimen that included influenza NP. Furthermore, we have constructed several fusion proteins of conserved genes
of influenza virus and tested their expression in vitro and protective potential in vivo. The four-partite NP-M1-M2-NS1 fusion
antigen that has M2 sequence engineered in the middle part of the composite protein was shown to not be cytotoxic in vitro. A
three-partite fusion protein (consisting of NP, M1 and NS1) was expressed much more efficiently than the four-partite protein.
Both of these constructs provided statistically significant protection upon DNA vaccination, with construct NP-M1-M2-NS1
being the most effective. We conclude that incorporation of M2 into a vaccination regimen may be beneficial only when its
apparent cytotoxicity-linked negative effects are neutralized. The possible significance of this data for influenza vaccination
regimens and preparations is discussed.
Citation: Ilyinskii PO, Gambaryan AS, Meriin AB, Gabai V, Kartashov A, et al (2008) Inhibition of Influenza M2-Induced Cell Death Alleviates Its Negative
Contribution to Vaccination Efficiency. PLoS ONE 3(1): e1417. doi:10.1371/journal.pone.0001417
INTRODUCTION
M2 of influenza A virus is a 97-amino acid ion channel protein.
M2 forms tetramers and is expressed at high density in the plasma
membrane of infected cells. M2 transmembrane domain is highly
conserved for all human, swine, equine, and avian strains of
influenza A virus and is primarily responsible for proton
translocation. This region is considered to be a target for the
antiviral drugs, amantidine and rimantadine, that have been used
for influenza prophylaxis and treatment over several decades [1].
M2 residues 1–24 comprise the extracellular domain (M2e),
which is a target for antibody-mediated immunity. M2e is also
extremely conserved. Since monoclonal antibodies to M2e were
shown to provide protection against influenza-induced disease [2],
various approaches utilizing M2e as part of a vaccine regimen
have been evaluated as possible components of a broad-spectrum
anti-influenza vaccine. Several reports presented evidence of high
protection after DNA immunization with high doses of M2-
encoding plasmid [3,4], with one group reporting immunization
with a combination of influenza nucleoprotein (NP) and M2 as the
most efficient [4]. However, it is also known that excessive
immunization with M2 fails to produce proportionate protection
[5]. Moreover, when M2e domain was fused to NP, immunization
of swine with such a DNA construct actually exacerbated the
disease [6].
We recently reported that expression of influenza A virus M2
protein is highly toxic for mammalian cells in vitro and that its
transmembrane region is essential for this function [7]. While
similar observations have been made in yeast and insect cells, it
was assumed that in heterotypic vertebrate expression systems, M2
causes no overt toxicity [8]. Contrary to that, we detected a
significant M2-driven cytotoxic effect in 293 HEK cells, which was
clearly linked to the proton-channeling ability of M2, with notable
changes in mitochondria of pM2-transfected cells observed within
the same time-period.
We hypothesized that M2-induced cytotoxicity may contribute
negatively to the efficiency of recombinant and/or attenuated
vaccines and that this is a molecular mechanism of the effect often
called ‘‘insufficient M2 immunogenicity’’. Indeed, we observed
that adding a plasmid encoding a full-size M2 to the NP-based
DNA vaccination regimen had a negative effect on animal survival
following high-dose viral challenge. Furthermore, we observed
that DNA vaccination with a multi-gene fusion construct (NP-M1-
M2-NS1) that contains full size M2 and is not cytotoxic in vitro had
a protective benefit that exceeds that of the construct that lacks M2
(NP-M1-NS1).
MATERIALS AND METHODS
Plasmids and cells
The construction of NP and M2-containing plasmids (pNP and
pM2) has been described earlier [7,9]. Construction of plasmids
encoding multi-gene fusion proteins NP-M1-NS1 (pNPM1NS1)
and NP-M1-M2-NS1 (pNPM1M2NS1) was done by PCR-
amplification from earlier described NP-, M1, NS1- and M2-
expressing plasmids [7,9]. Viral sequences were as follows: NP
from strain A/WSN/33-H1N1, which is identical to A/PR/8/34-
H1N1 on the amino acid level [9], M1 from the same strain, NS1
from strain A/PR/8/34-H1N1 and M2 from influenza A/WSN/
33 (H1N1) strain (GenBank accession numbers: V01084, L25818,
J02150 and L25818, correspondingly). Multi-gene sequences were
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first inserted into the pcDNA vector (Invitrogen, Carlsbad, CA,
USA). HA-tag-encoding sequences were added at the 39-termini
and Flag-tag-encoding sequences were attached to 59-termini of
NP-M1-NS1 and NP-M1-NS1-M2 genes to enable their efficient
immunological detection. All sequences were then cloned into the
pCAGGS expression vector and used for expression testing and
immunization [10].
Transfection
293 HEK cells were transfected at 60–80% confluency in 35 mm
plates with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA)
overnight (1.5 mg of total plasmid DNA per 5 ml LF2000). EGFP-
expressing plasmid (0.5 mg) was used for co-transfection with
pNPM1NS1 and pNPM1M2NS1 to visualize transfected cells
(transfection efficiency was 80–90%). Control cells were transfect-
ed with the same amount of empty vector pCAGGS.
Western blotting
Cells were lysed at 24 hours after transfection, normalized for
protein concentration, and following SDS-PAGE and immuno-
blotting, NPM1NS1 and NPM1M2NS1 expression was detected
using either anti-HA-tag or anti-Flag antibodies (Cell Signaling,
Beverly, MA, USA).
Cytotoxicity
In transfected cells was measured as a function of loss of GFP
fluorescence as previously described [7]. Quantification of cell
death was made by propidium iodide (PI) staining (5 mg/ml,
10 min). Images were taken at 16–90 hours after transfection
under a fluorescent microscope (106 or 406 objective).
Immunization with pNP, pM2, pNPM1NS1 and
pNPM1M2NS1 in vivo
In the first experiment 5 mg of pNP, pM2 or pCAGGS (control) in
100 ml of PBS was injected intramuscularly per mouse per
vaccination. Since the group immunized with a combination of
pNP and pM2 received 10 mg of DNA total, the amount of DNA
in other experimental groups was adjusted correspondingly with
pCAGGS plasmid. Therefore, mice in the pNP group received
5 mg of pNP and 5 mg of pGACCS, mice in the pM2 group
received 5 mg of pM2 and 5 mg of pGACCS, mice in the vector-
immunized group received 10 mg of pGACCS. The size of the
experimental groups was 20–22 animals per group with the
exception of the control group of intact mice that comprised 10
animals. Mice were subjected to immunization with plasmid DNA
three times with 14 days interval in between. Animal survival,
weights and virus titers were monitored. For immunization with
multi-gene fusion plasmids pNPM1NS1 and pNPM1M2NS1
25 mg of each plasmid was used. Mice (9–10 per group) were
subjected to immunization with plasmid DNA three times with 14
days interval in between.
Mouse-adapted influenza virus and animal infection
Avian influenza virus A/Mallard/Pennsylvania/10218/84
(H5N2) was obtained from the virus depository of the Virology
Department of St. Jude Children’s Research Hospital (Memphis,
TN, USA) and was adapted to mice by lung-to-lung passage
[11,12]. Virus was propagated in 10-day-old embryonated chicken
eggs. The virus-containing allantoic fluid was stored at270uC and
titrated in chicken embryo or in MDCK cells. Ether anaesthetized
BALB/c mice (10–12 g) were infected intranasally with 50 ml of
PBS-diluted allantoic fluid containing 5, 10 or 100 LD50 of A/
Mallard/Pennsylvania/10218/84, 7 days after the last boost.
Protection was measured by monitoring animal survival and body
weight, which was assessed throughout an observation period of 21
days. Severely affected mice were euthanized. 1 LD50 of A/
Mallard/Pennsylvania/10218/84 is equal to 100–1000 TCID50.
Lung tissues from infected animals (2 from each group) were taken
at day 4 after infection for viral titer evaluation. Viral titers were
measured by focus assay in MDCK cells that were grown in 24-
well plates and incubated with 0.5 ml/well of 10-fold sample
dilutions. After 60-min absorption at RT, the virus inoculum was
removed, cells washed and covered with 1% agarose. 50 hrs later,
cells were fixed and incubated for 1 h with anti-influenza virus
antibodies and visualized using peroxidase staining. Stained foci
(PFU) were counted and titers calculated by the routine Reed &
Muench method.
Statistical methods
Standard error (SE) of a percent value was determined by the
formula: SE= !p(1002p)/n, where p is percent value and n is
number of animals used, similarly to that previously described
[11]. Significance between two percent values (with probability
0.95): t = p12p2/!SE12+SE22.2.0. Animal survival was compared
using log-rank test (PROC LIFETEST, SAS(R) statistical
package). The differences at P-value below 0.05 were considered
significant.
RESULTS
Inclusion of M2-encoding plasmid into vaccination
regimen may result in disease exacerbation
The level of protection provided by DNA vaccination with pNP,
pM2, pNP+pM2 or vector plasmid was assessed for animal groups
challenged with 100 LD50 of mouse-adapted H5N2 influenza virus.
Vaccination with pNP resulted in 20% survival (Fig. 1). Protection
data unequivocally suggested that in such experimental settings
inclusion of pM2 into the immunization regimen is detrimental for
protection (Fig. 1). Specifically, while the pM2-immunized group
showed no effect on the dynamics of survival and disease similar to
vector-immunized controls, the survival in pNP+pM2-immunized
group was clearly impaired compared to immunization with pNP
Figure 1. Survival of mice vaccinated with the combinations of pNP
and pM2 after challenge with 100 LD50 of H5N2 influenza virus
strain A/Mallard/Pennsylvania/10218/84. Animals were immunized
and challenged as described in Materials and Methods.
doi:10.1371/journal.pone.0001417.g001
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alone (Fig. 1) and this difference was statistically significant
(p,0.05). There was no difference in viral titers between pNP
and pNP+pM2 immunized groups, with the titer in the pM2-
immunized group being somewhat lower (not shown).
Expression of fusion proteins derived from
conserved influenza genes
Plasmids encoding fusion genes, pNPM1NS1 and
pNPM1M2NS1, that contained full sequences of conserved
influenza NP, M1 and NS1 genes (with or without M2) were
constructed and shown to express the proteins of predicted size
(Fig. 2). They were tested for their expression in vitro using
antibodies to N-terminal Flag-tag (Fig. 2A) or C-terminal HA-tag
(Fig. 2B). It was clear that inclusion of M2-encoding sequence
resulted in dramatic impairment of expression of the fusion
proteins, with NPM1NS1 construct expressing at least 10 times
more efficiently than NPM1M2NS1 (Fig. 2A). Higher levels of
expression of the three-partite over four-partite fusion protein was
also seen when antibody to C-terminal HA-tag was used (Fig. 2B),
although the overall difference was less. Neither of the fusion
proteins exhibited any cytotoxicity similar to that induced by wild-
type M2 (Fig. 3). Specifically, for NPM1M2NS1 no signs of
cytotoxicity were seen up to 96 hours after transfection even when
its efficiency of transfection was 90–100% (not shown).
Protection of mice from disease by immunization
with plasmids encoding fusion proteins of influenza
virus
We utilized both multi-partite fusion constructs in vaccination
experiments in order to test whether the utilization of M2 in a
fashion that alleviates its cytotoxicity is capable of providing
additional protective benefit (Fig. 4). Weakly expressed
NPM1M2NS1 construct resulted in partial protection against 5
LD50 of mouse-adapted H5N2 virus, which was statistically
significant (p,0.05) and exceeded that exhibited by the much
more efficiently expressed NPM1NS1 construct which did not
include M2, although the latter also provided statistically
significant protection as shown by log-rank analysis.
DISCUSSION
The usefulness of the immune response against M2 for protection
against influenza-induced disease has been known for a long time
and multiple attempts have been undertaken to exploit this for the
generation of cross-protective vaccine preparations [3,4,13,14,15].
Despite significant advances along this route, this aim has not been
Figure 2. Expression of recombinant multi-partite fusion proteins
based on conserved genes of influenza in vitro. Lanes 1–4 - cells
transfected with pNPM1NS1, lanes 5–8 - with pNPM1M2NS1. A - anti-
Flag-tag antibodies used for protein detection; B - anti-HA-tag
antibodies used. Lanes 1, 2, 5 and 6 - starting point of chase (0 hours).
Chase time: 3.5 hours (panel A, lanes 3 and 7), 7 hours (panel A, lanes 4
and 8), 8 hours (panel B, lanes 3, 4, 7 and 8). Proteosome inhibitor
MG132 added to samples in panel B, lanes 4 and 8. Lanes 1 and 5
contain M of total protein loaded to lanes 2–4 and 6–8, correspond-
ingly. Position of molecular weight markers is shown.
doi:10.1371/journal.pone.0001417.g002
Figure 3. Absence of cytotoxicity induced by multi-partite fusion
proteins based on conserved genes of influenza containing and not
containing M2 sequence (as measured by green fluorescence). HEK
cells were co-transfected with 0.2 mg of pGFP and 0.8 mg of the
following plasmids: A - pCAGGS, B - pM2, C - pNPM1NS1, D -
pNPM1M2NS1. Images were taken 64 hours after transfection.
doi:10.1371/journal.pone.0001417.g003
Figure 4. Survival of mice vaccinated with pNPM1NS1 and
pNPM1M2NS1 after challenge with 5 LD50 of H5N2 influenza virus
strain A/Mallard/Pennsylvania/10218/84. Animals were immunized
and challenged as described in Materials and Methods.
doi:10.1371/journal.pone.0001417.g004
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accomplished. Moreover, in several experimental settings, the
results have been disappointing [6]. Our results presented herein
(Fig. 1) coupled with earlier accumulated data [6] clearly indicate
that immunization with M2 may lead to disease exacerbation.
Our data point to the possibility that M2-dependent cytotoxicity
is a factor in influenza pathogenesis, and also raises the question
whether any vaccine (recombinant, live-attenuated or to a lesser
extent inactivated) containing full-size functional M2 may be
detrimental or even harmful. The molecular mechanism of this
negative action of M2 may be, at least in part, linked to its
cytotoxic effect which we have recently described [7]. If M2-
induced cytotoxicity is linked to suppression of the immune
response in M2-containing vaccines, then the incorporation of
influenza M2 into a vaccination regimen should include the
neutralization of its possible negative effects.
There are several approaches on how to neutralize M2
cytotoxic activity. In particular, it is possible to incorporate M2
into a multi-gene fusion construct, designed to limit the
accessibility of M2 functional domains. We have recently
demonstrated that addition of M1 and NS1 to NP is advantageous
in several animal models of DNA vaccination [9]. In this study, we
tested a fusion gene including these conserved influenza genes with
or without M2, with the sequence of the latter engineered to be
inside and not on the termini of the fused gene (resulting in
NPM1M2NS1 construct).
The expression level of this NPM1M2NS1 fusion protein was at
least 10 times lower than that of NPM1NS1 (Fig. 2). At the same
time, the incorporation of M2 sequence into the third position of
the recombinant molecule did not result in any overt cytotoxicity
in vitro, different from full-size M2 (Fig. 3). Additionally, the four-
partite NPM1M2NS1 fusion protein was more protective than
NPM1NS1 protein in a DNA vaccination model, while expressed
at significantly lower levels (Figs. 3, 4). It is plausible to suggest that
some of the detrimental effects exhibited by M2 are alleviated
when it is placed in the central position of the recombinant protein
and therefore the resulting protein is not cytotoxic.
Collectively, it is reasonable to suggest that expression of wt-M2
protein, although useful as an antigen, also contributes negatively
to the vaccination regimen by virtue of its cytotoxic capacity.
Therefore, successful utilization of M2 in anti-influenza immuni-
zation may require elimination of its cytotoxicity without
interfering with its antigenic epitopes. This may have been
partially accomplished in approaches that employ M2e domain
[14,15]. Incorporation of full M2 sequence into multi-gene
recombinant structures based on conserved influenza proteins is
yet another avenue to attain this goal as was accomplished with the
NPM1M2NS1 fusion construct described herein. This may in turn
be complemented by M2 site-specific mutagenesis. We have
previously reported that introducing hydrophobic amino acids
within the ion channel formed by M2 tetramer is an effective
strategy to reduce M2 cytotoxicity [7].
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